A Phase 4 interventional study of Paracetamol and Phenylephrine in Influenza and Common Cold, sponsored by GlaxoSmithKline. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-01.
Sponsored by GlaxoSmithKline · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 152nd largest by enrollment of the 165 interventional ones that give a count, is one of 16 that started in 2011, is one of 12 in phase 4, and was the 123rd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–64 · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65+ · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65–85
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 56 · Phase 3 74 · Phase 4 12
First in 2002; this study’s year is marked. 16 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 324 across the 165 interventional studies, 605 across the 22 observational. Of the 178 that completed or were terminated, 132 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Influenza, Human by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT07464314GlaxoSmithKlineA Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets. The study will also assess the gastrointestinal transit of two oral cold and influenza ('flu') formulations using gamma scintigraphy. It is postulated that paracetamol in solution, such as from cold and 'flu' hot remedies, provides a greater early exposure compared to standard paracetamol tablets. In addition, the pharmacokinetic (PK) profile of paracetamol in the two formulations will be investigated.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
Drug: Paracetamol · Drug: Phenylephrine · Drug: Ascorbic Acid
Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
Drug: Paracetamol
Present in both test and active comparator
Test product
Test product
Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter)
Time to reach plasma paracetamol concentration of 0.25 μg/mL was determined using plasma concentration time profiles.
Time frame: Blood samples taken within 15-30 minutes prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min)
AUC (0-30 min) was determined from paracetamol plasma concentration time profiles using trapezoidal rule.
Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
AUC (0-60 Min)
AUC (0-60 min) was determined from paracetamol plasma concentration time profiles using trapezoidal method.
Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Maximum Plasma Concentration (Cmax)
Cmax was determined using plasma paracetamol concentration time profile.
Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Time to Maximum Plasma Concentration (Tmax)
Time after administration when the maximum plasma concentration was reached.
Time frame: Blood samples taken within 15-30 min prior to dosing and at 3, 5, 7, 9, 11, 15, 20, 30, 45, 90, 120 and 180 minutes post-dose
Time to Onset of Gastric Emptying
The individual anterior and posterior images were assessed using Gamma Scintigraphy images and WebLink Image Analysis program to determine the time to onset of gastric emptying of hot drink remedy and standard paracetamol tablets.
Time frame: Baseline to 10 hours
Time to Completion of Gastric Emptying
Time to completion of gastric emptying of hot drink remedy and standard paracetamol tablets was assessed using Gamma Scintigraphy images and WebLink image analysis program. Completion of gastric emptying was confirmed by two consecutive images with negligible gastric activity.
Time frame: Baseline to 10 hours
Time to Onset and Completion of Disintegration of Reference Tablets
Qualitative onset and completion of tablet disintegration was determined using Gamma scintigraphy images and WebLink image analysis program.
Time frame: Baseline to 10 hours post dose
Participants were recruited at one clinical study site in Glasgow.
| Milestone | Hot Drink Remedy First, Then Standard Paracetamol Tablets | Standard Paracetamol Tablets First, Then Hot Drink Remedy |
|---|---|---|
| Started | 12 | 13 |
| Completed | 12 | 13 |
| Not completed | 0 | 0 |
| Milestone | Hot Drink Remedy First, Then Standard Paracetamol Tablets | Standard Paracetamol Tablets First, Then Hot Drink Remedy |
|---|---|---|
| Started | 12 | 13 |
| Completed | 12 | 13 |
| Not completed | 0 | 0 |
| Milestone | Hot Drink Remedy First, Then Standard Paracetamol Tablets | Standard Paracetamol Tablets First, Then Hot Drink Remedy |
|---|---|---|
| Started | 12 | 13 |
| Completed | 12 | 13 |
| Not completed | 0 | 0 |
Time to reach plasma paracetamol concentration of 0.25 μg/mL was determined using plasma concentration time profiles.
| minutes | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Time to Reach Plasma Paracetamol Concentration of 0.25 μg/mL (Microgram Per Milliliter) | 4.59 (3.4 to 11.1) | 23.14 (6.0 to 46.6) |
AUC (0-30 min) was determined from paracetamol plasma concentration time profiles using trapezoidal rule.
| nanograms (ng)*hours (h)/mL | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Area Under the Concentration/Time Curve From 0 to 30 Minutes (Min) (AUC 0-30 Min) | 1535.80 ± 873.300 | 387.28 ± 363.139 |
AUC (0-60 min) was determined from paracetamol plasma concentration time profiles using trapezoidal method.
| ng*h/mL | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| AUC (0-60 Min) | 5007.11 ± 1890.135 | 1874.22 ± 1555.539 |
Cmax was determined using plasma paracetamol concentration time profile.
| ng/mL | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Maximum Plasma Concentration (Cmax) | 8309.58 ± 2109.196 | 9225.20 ± 1681.200 |
Time after administration when the maximum plasma concentration was reached.
| hours | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 1.50 (0.2 to 2.0) | 1.99 (0.7 to 3.0) |
The individual anterior and posterior images were assessed using Gamma Scintigraphy images and WebLink Image Analysis program to determine the time to onset of gastric emptying of hot drink remedy and standard paracetamol tablets.
| minutes | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Time to Onset of Gastric Emptying | 7.86 ± 3.909 | 54.23 ± 3.596 |
Time to completion of gastric emptying of hot drink remedy and standard paracetamol tablets was assessed using Gamma Scintigraphy images and WebLink image analysis program. Completion of gastric emptying was confirmed by two consecutive images with negligible gastric activity.
| minutes | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| Time to Completion of Gastric Emptying | 202.59 ± 16.811 | 168.38 ± 15.463 |
Qualitative onset and completion of tablet disintegration was determined using Gamma scintigraphy images and WebLink image analysis program.
| minutes | Standard Paracetamol Tablets |
|---|---|
| Onset Time of Disintegration | 42.50 ± 18.028 |
| Completion Time of Disintegration | 62.88 ± 24.788 |
Collected over Adverse events were collected from the start of the treatment, and until 5 days following administration of the last dose of investigational product.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hot Drink Remedy | — | 0/25 (0%) | 3/25 (12%) |
| Standard Paracetamol Tablets | — | 0/25 (0%) | 3/25 (12%) |
| Event | Hot Drink Remedy | Standard Paracetamol Tablets |
|---|---|---|
| HematuriaRenal and urinary disorders | 2/25 | 0/25 |
| Alanine Aminotransferase IncreasedInvestigations | 0/25 | 1/25 |
| Blood Bilirubin IncreasedInvestigations | 0/25 | 1/25 |
| BlepharospasmEye disorders | 1/25 | 0/25 |
| HeadacheNervous system disorders | 0/25 | 1/25 |
| Age, Continuous(Years) | All Randomized Participants |
|---|---|
| Mean | 30.5 ± 11.23 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 0 |
| Male | 25 |
The record gives a start of May 2011, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Phenylephrine · Ascorbic Acid